Intratio
Loading...
Skip to main content
Model output · Signal date Oct. 14, 2026

Daily Signals

2482 companies scored · 2026-10-14 run in progress: 3417 of ~5379 signals so far · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-14 Cut-offs from the 2026-10-13 run
Companies scored 2482 IC ≥ 0 · market cap ≥ $100M
Median forecast +0.26% Alpha · 90D
Long–short spread +3.95% Strong Buy minus Strong Sell, mean
Median IC 0.29 Spearman · 90D
Rating changes ▲ 54 ▼ 58 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

287 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
251 ACOGAlpha Cognition Inc. Life Sciences 0.43 $193M Unlock rating and forecasts
252 IVVDInvivyd, Inc. Life Sciences 0.52 $190M Unlock rating and forecasts
253 ELDNEledon Pharmaceuticals, Inc. Life Sciences 0.00 $190M Neutral +0.38% +0.40% ·
254 TRDAEntrada Therapeutics, Inc. Life Sciences 0.20 $189M Unlock rating and forecasts
255 CGENCOMPUGEN LTD Life Sciences 0.43 $187M Neutral -0.10% -0.19% ·
256 LYELLyell Immunopharma, Inc. Life Sciences 0.16 $184M Unlock rating and forecasts
257 STROSUTRO BIOPHARMA, INC. Life Sciences 0.59 $183M Unlock rating and forecasts
258 ORMPORAMED PHARMACEUTICALS INC. Life Sciences 0.11 $173M Unlock rating and forecasts
259 PEPGPepGen Inc. Life Sciences 0.38 $173M Unlock rating and forecasts
260 ZNTLZentalis Pharmaceuticals, Inc. Life Sciences 0.31 $172M Unlock rating and forecasts
261 CHRSCoherus Oncology, Inc. Life Sciences 0.15 $165M Unlock rating and forecasts
262 MDWDMediWound Ltd. Life Sciences 0.26 $157M Unlock rating and forecasts
263 ORGOOrganogenesis Holdings Inc. Life Sciences 0.37 $156M Unlock rating and forecasts
264 TARAProtara Therapeutics, Inc. Life Sciences 0.17 $155M Unlock rating and forecasts
265 CMPXCompass Therapeutics, Inc. Life Sciences 0.30 $154M Unlock rating and forecasts
266 PYXSPyxis Oncology, Inc. Life Sciences 0.05 $154M Unlock rating and forecasts
267 MOLNMOLECULAR PARTNERS AG Life Sciences 0.02 $153M Neutral -0.09% +0.13% ·
268 NKTXNkarta, Inc. Life Sciences 0.26 $150M Unlock rating and forecasts
269 AVXLANAVEX LIFE SCIENCES CORP. Life Sciences 0.03 $137M Neutral +0.23% +0.03% ·
270 ANTXAN2 Therapeutics, Inc. Life Sciences 0.11 $136M Unlock rating and forecasts
271 ALXOALX ONCOLOGY HOLDINGS INC Life Sciences 0.24 $135M Unlock rating and forecasts
272 ABOSAcumen Pharmaceuticals, Inc. Life Sciences 0.19 $131M Unlock rating and forecasts
273 KRROKorro Bio, Inc. Life Sciences 0.13 $130M Unlock rating and forecasts
274 NERVMinerva Neurosciences, Inc. Life Sciences 0.14 $120M Neutral +0.45% +0.38% ·
275 NRXPNRX Pharmaceuticals, Inc. Life Sciences 0.01 $117M Unlock rating and forecasts
276 TNYATenaya Therapeutics, Inc. Life Sciences 0.08 $117M Unlock rating and forecasts
277 GNLXGENELUX Corp Life Sciences 0.32 $114M Neutral +0.38% +0.49% ·
278 IFRXInflaRx N.V. Life Sciences 0.22 $112M Neutral -0.12% +0.36% ·
279 MSLESatellos Bioscience Inc. Life Sciences 0.39 $111M Unlock rating and forecasts
280 CLLSCellectis S.A. Life Sciences 0.13 $110M Neutral +1.34% -0.03% ·
281 FHTXFoghorn Therapeutics Inc. Life Sciences 0.13 $110M Unlock rating and forecasts
282 ENGNenGene Therapeutics Inc. Life Sciences 0.40 $109M Unlock rating and forecasts
283 CPIXCUMBERLAND PHARMACEUTICALS INC Life Sciences 0.42 $107M Unlock rating and forecasts
284 LENZLENZ Therapeutics, Inc. Life Sciences 0.58 $107M Neutral -0.08% -0.52% ▲ 1
285 UNCYUnicycive Therapeutics, Inc. Life Sciences 0.12 $104M Unlock rating and forecasts
286 INOINOVIO PHARMACEUTICALS, INC. Life Sciences 0.23 $103M Unlock rating and forecasts
287 RANIRani Therapeutics Holdings, Inc. Life Sciences 0.21 $102M Unlock rating and forecasts
251–287 of 287 Previous Next
Since the previous run

Rating changes

▲ 54▼ 58
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-13) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.